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Megadose bolus heparin as first treatment lor acute 
myocardial infarction: results of the HEAP pilotstudy
F.W.A. Verheugt, R.C. Marsh, G. Veen, J.G.F, Bronzwaer, F.J. Zijlstra. North 
Colorado Medical Center, Greeley, CO, USA; Free University, Amsterdam, 
University of Nijmegen, Nijmegen; Weezenianden HospitalZwolle, The 
Netherlands
Early angiography after thrombolysis for acute myocardial infarction (AMI) 
shows better patency when intravenous (iv) heparin is used as adjunct. We 
wondered, if iv heparin alone also would induce reperfusion.
In the HEAP (Heparin in Early Patency) Pilot study 73 patients (pts) with <
6 hours (h) signs (>2 mm STf in > 2 leads) and symptoms of AMI received a 
single iv bolus of 300 U/kg heparin, a dose usually given by cardiac surgeons 
prior to cardiopulmonary bypass. Doses of bolus heparin given varied from 
10,000 to 40,000 U. Aspirin (160 mg chewed), but no thrombolytic agent was 
given. Patency was assessed by coronary angiography at 90 minutes (min) 
after the heparin bolus.
In 38/73 (52%) pts TIMI flow 2-3 was seen at 90 min: TIMI flow 3 in 24 
(33%) pts and TIMI flow 2 in 14 (19%) pts. Pts with < 2 h symptoms (n = 34) 
had 68% TIMI flow 2-3 vs 39% in pts with > 2 h symptoms (p = 0.09). Pts 
with TIMI flow 0-2 underwent primary angioplasty. At 90 min aPTT exceeded 
120 sec in all pts. No bleeding was seen. Aspirin 80 mg daily was given, as 
was heparin (aPTT 2.0-2.5) for 48 h. Predischarge anglo showed TIMI flow 3 
in 18/23 (78%) pts.
Thus, early therapy with high-dose front-loaded heparin alone can induce 
full coronary reperfuslon in pts with AMI, especially in early (<2 h) pts. This 
simple, inexpensive and easily antagonizable strategy seems to be an attractive 
first AMI treatment both pre-hospitai, and in-hospital prior to primary PTCA. 
However, high-dose bolus heparin should be compared first to the regular low- 
dose heparin, for which a randomized angiographic study is currently carried 
out.
733 High-dose intravenous heparin as an alternative to 
thrombolytics in the treatment of patients with acute 
myocardial infarction -  The HAPI study
Fábio P. Esteves, Júlio C. Braga, Adriana Latado, A. Azevedo Jr., José
C. Brito, Antônlo J. Neri Sousa, Mario S, Rocha, Alvaro Rabelo Jr., J, Péneles 
Esteves. Hospiial Portugués and Fundaçâo Baiana de Cardiologia, Salvador, 
Brazil
Background: Pre-hospital chemical thrombolysis is effective in the early phase 
of Acute Myocardial Infarction (AMI), but has been hampered by the need for 
diagnosis confirmation by ECG criteria, contraindication check-list and difficult 
utilization of thrombolytics outside hospital. Standard Heparin (SH) has been 
used as an alternative or as an adjunctive for chemical, mechanical as well as 
endogenous thrombolysis, in patients (P) admitted to the hospital with AMI.
Aim: We tested the hypothesis that a high dose IV SH bolus could open 
occluded artery related to infarction (ARI) in an acceptable rate, being an 
alternative way for pre-hospital thrombolysis or as a pre-treatment before 
primary PTCA, at low complication level and cost.
Methods: Thirty-two P, mean age of 64 ±  10 years, 47% male, presenting 
within 12 h symptoms of AMI and indication criteria for reperfusion (chest pain, 
ST elevation on standard ECG) were randomized (double blind fashion) to SH, 
300 lU/kg IV bolus or placebo (P1). All P received 200 mg ASA before being 
submitted to immediate coronariography, for intended primary PTCA.
Results: There was no difference between the two groups in relation to 
time of beginning of symptoms (mean of 4.3 ±  3.2 h). Coronaryography was 
performed with a mean delay of 74 ±  20 min. SH group (n = 16) had 50% and 
P1 group (n = 16) 12.5% TIMI 2.3 ARI patency respectively (p = 0.05). All P 
with occluded ARI (TIMI 0.1) or TIMI 2.3 but critical obstruction were submitted 
to primary PTCA, at the discretion of the hemodynamicist.
Conclusions: 1) Standard heparin does have a thrombolytic action when 
administered in high dosage IV bolus. 2) The infrequent contraindication for 
its prescription, tow incidence of harmful effects, no need for confirmation of 
diagnosis by a cardiologist neither ECG comprovation, may suggest its routine 
utilization fn outpatients with suspected acute coronary syndromes before they 
get to the hospital or to inpatients waiting for intended primary PTCA.
IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
Safety and efficacy of reduced defibrillation energiek 
implantable cardioverter defibrillators: results of the 
LEET study, a prospective, randomized multicenter tra
E.G. Vester, J. Neutzner1, E. Himmrich2, A. Heise3, U.S. Ganschow. 
University Düsseldorf; 1 Kerkhoff Clinic, Bad Nauheim; 2 University Mainz;
3 University Homburg, Germany
For patients (pts) convenience the size of implantable cardioverter de fife  
(ICD) should be reduced. With the lowering of maximal defibrillation e*ñ 
(DE) smaller capcitors can be used. A prospective, randomized study haste 
set up to evaluate the safety and efficacy of using ICDs at lower DE in 
ICD pts.
We enrolled 142 consecutive ICD recipients with documented venïfcè 
fibrillation (VF), polymorphic ventricular tachycardia (VT) or monomorptii; 
unresponsive to antitachycardia pacing by four participating centers: 132e 
(93%) (mean age 58 ±  12 years, LVEF: 36 ±  13%, CAD: 64%, DCM: 23%}r= 
the inclusion criteria requiring an intraoperative defibrillation threshold (OFT) 
15 Joule (J) by using only endocardial single lead systems (Entfotak) andfc: 
generation ICDs. These pts have been randomized to either a test group;? 
pts, LVEF: 38.3 ±  14%, DFT: 9.3 ±  3 J) with first shock DE set at twotr; 
DFT, or a control group (63 pts, LVEF: 35.4 ±  13%, DFT: 10.1 ±  4 J) wnM: 
shock set at 34 J (maximum output (MO)). All other shocks were set on MOr 
both groups. The follow up period was 9.8 db 6 months.
The first shock efficacy i.e. the rate of successful termination of a susîre 
VT/VF episode by the first shock, amounted to 98% in the 204 episod«: 
ventricular tachyarrhythmias (VTA) in the test group and to 97% in the 12 
episodes with VTA in the control group (‘p = ns). Two deaths (one sute 
occurred in each group (overall mortality 3%).
Conclusion: ICDs with first shock set at two times DFT appear to be f ­
and as efficient as ICDs set on MO in pts with malignant VT/VF. These 
suggest that pts with low intraoperative DFT may be treated with smaller, ft* 
output devices even using the single lead alone technique.
Benefit from implanted cardioverter-defibrillators 
implantation in patients with overt heart failure
D. Böcker, M. Block, D. Bänsch, D. Hammel1, M. Weber, J. Brunn,
M. Castruccl, M. Borggrefe, G. Breithardt. University Hospital, Department 
Cardiology; 1 University Hospital, Department of Cardiothoracic Surgery, 
Münster, Germany
Objective: In the absence of prospective studies, benefit from the rap/1: 
implanted cardioverter-defibrillators (ICD) has been questioned inpatients*: 
advanced heart failure. The purpose of this study was to investigate wh# 
implantation of an ICD is likely to improve outcome in patients with overt te 
failure.
Methods: Between 1989 and 1995, 462 patients (62% CAD, 18% 03 
were treated with an ICD with extended memory functions (RR-interra: 
electrograms from treated episodes) in combination with endocardial ter 
Retrospectively, we correlated the stage of heart failure with the recuse : 
of fast ventricular tachyarrhythmias (VT/VF; > 240/min) and overall mc/r 
The potential benefit imposed by implantation of an ICD was estimated sss 
difference between overall mortality and the occurrence of fast and wr¿ 
termination by the devices presumably fatal ventricular tachyarrhythmia* 
Results: Independent of the stage of heart failure, a significant differ; 
between recurrences of fast ventricular tachyarrhythmias and overalf mo# 
was observed suggesting a benefit from iCD-implantation in all groups.
3-year event rates NYHA 1 NYHA 2 NYHA 3
n 107 221 134
Fast VT/VF (> 240 bpm) 34% 33% 43%
Overall mortality 2% 14% 24%
Estimated benefit 32% 19% 19%
In the NYHA 3-group, no differences were observed between patients r  
an ejection fraction above versus below 30%.
Conclusions: The stage of heart failure is an important determinant fors=jv.: 
after implantation of an ICD. However, implantation of an ICD-system isfc 
to improve survival significantly in all stages of heart failure. Even p^f: 
with advanced heart failure and low ejection fraction are likely to bene*!- 
ICD-implantation.
